TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HURA TuHURA Biosciences, Inc.

盘后交易 10-08 16:56:31 EDT

1.93

-0.05

-2.53%

盘后1.93

+0.000.00%

16:32 EDT

最高1.97	最低1.89	成交量31.62万
今开1.95	昨收1.98	日振幅4.04%
总市值1.23亿	流通市值7,654万	总股本6,358万
成交额61.19万	换手率0.80%	流通股本3,966万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":1.93,"timestamp":1791489600000,"preClose":1.98,"halted":0,"volume":316205,"hourTrading":{"tag":"盘后","latestPrice":1.93,"preClose":1.93,"latestTime":"16:32 EDT","volume":81658,"amount":157600.0134922,"timestamp":1791491572539,"change":0,"changeRate":0,"amplitude":0.020725},"delay":0,"changeRate":-0.025252525252525276,"floatShares":39657200,"shares":63578528,"eps":-0.542788,"marketStatus":"盘后交易","change":-0.05,"latestTime":"10-08 16:56:31 EDT","open":1.95,"high":1.97,"low":1.89,"amount":611852.8805399999,"amplitude":0.040404,"askPrice":1.97,"askSize":100,"bidPrice":1.91,"bidSize":86,"shortable":3,"etf":0,"ttmEps":-0.542788,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791504000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.98,"preHourTrading":{"tag":"盘前","latestPrice":1.97,"preClose":1.98,"latestTime":"09:29 EDT","volume":476,"amount":937.72,"timestamp":1791466199999,"change":-0.01,"changeRate":-0.005051,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.93,"preClose":1.93,"latestTime":"16:32 EDT","volume":81658,"amount":157600.0134922,"timestamp":1791491572539,"change":0,"changeRate":0,"amplitude":0.020725},"volumeRatio":1.296934},"requestUrl":"/m/hq/s/HURA","defaultTab":"news","newsList":[{"id":"1157680158","title":"Tuhura Biosciences 获FDA“可开展研究”通知及IND许可，用于评估其TBS-2025 VISTA抑制抗体在特定分子亚型急性髓系白血病及其他血液相关癌症中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1157680158","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157680158?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:46","pubTimestamp":1789386371,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences 已收到美国食品药品监督管理局的“可开展研究”通知，并获得了新药临床研究申请的批准。此次获批，旨在支持其研发的TBS-2025 VISTA抑制抗体，用于针对特定分子定义的急性髓系白血病及其他血液相关癌症亚群进行评估。FDA的放行，意味着Tuhura Biosciences可以启动相关临床试验，以深入探究TBS-2025在明确界定的患者群体中的安全性、耐受性及初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139203859","title":"Tuhura Biosciences：若应答率喜人，或与FDA探讨试验扩展及加速审批路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1139203859","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139203859?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:46","pubTimestamp":1789386370,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences透露，一旦试验应答率数据表现积极，公司可能会与美国食品药品监督管理局（FDA）协商，探讨扩大试验范围以及争取加速审批的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147397848","title":"TuHURA Biosciences提交新药临床试验申请，评估TBS-2025 VISTA抑制抗体在分子定义亚型AML及其他血液相关癌症中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1147397848","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147397848?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:50","pubTimestamp":1781524218,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences公司已提交一份新药临床试验申请，旨在评估其研发的TBS-2025 VISTA抑制抗体在分子定义亚型的急性髓系白血病及其他血液相关癌症中的疗效。TBS-2025作为一款靶向VISTA的抑制性抗体，其作用机制旨在调节肿瘤微环境，为那些现有疗法效果有限的AML及其他血液癌症患者提供新的潜在治疗选择。此次提交的申请将聚焦于通过分子特征定义的癌症亚组，体现了肿瘤学领域日益增长的个性化医疗趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136789265","title":"TuHURA生物科学公司与H.C. Wainwright & Co.达成市场发售协议 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1136789265","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136789265?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:35","pubTimestamp":1775680540,"startTime":"0","endTime":"0","summary":"TuHURA生物科学公司已与H.C. Wainwright & Co.正式签署市场发售协议，相关细节已通过美国证券交易委员会文件公开披露。该协议标志着公司在资本市场的战略布局取得新进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516049635","title":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖，给予买入评级, 目标价13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516049635","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516049635?lang=zh_cn&edition=full","pubTime":"2025-03-03 21:20","pubTimestamp":1741008040,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences(HURA.US)获HC Wainwright & Co.首次覆盖，给予买入评级, 目标价13.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03212048493051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HURA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintara.com","stockEarnings":[{"period":"1week","weight":-0.0571},{"period":"1month","weight":-0.0748},{"period":"3month","weight":-0.1538},{"period":"6month","weight":-0.1278},{"period":"1year","weight":-0.208},{"period":"ytd","weight":1.6166}],"compareEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.1439},{"period":"1year","weight":0.1616},{"period":"ytd","weight":0.1398}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TuHURA Biosciences, Inc.是一家内华达州公司，成立于2009年6月24日，名称为Berry Only，Inc。该公司是一家临床阶段的生物制药公司。Kintara致力于为医疗需求未得到满足的患者开发新型癌症疗法。Kintara公司正在开发两种晚期疗法，以降低风险，满足明确的未满足的医疗需求。这两个项目分别是VAL-083治疗胶质母细胞瘤（GBM）和REM-001治疗皮肤转移性乳腺癌（CMBC）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.054973},{"month":2,"riseRate":0.2,"avgChangeRate":0.076571},{"month":3,"riseRate":0.4,"avgChangeRate":0.006899},{"month":4,"riseRate":0.4,"avgChangeRate":-0.002636},{"month":5,"riseRate":0.6,"avgChangeRate":1.079221},{"month":6,"riseRate":0.5,"avgChangeRate":-0.03295},{"month":7,"riseRate":0.4,"avgChangeRate":-0.020468},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.080033},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.095152},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.110715},{"month":11,"riseRate":0.4,"avgChangeRate":-0.068131},{"month":12,"riseRate":0.2,"avgChangeRate":-0.220735}],"exchange":"NASDAQ","name":"TuHURA Biosciences, Inc.","nameEN":"TuHURA Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"TuHURA Biosciences, Inc.,HURA,TuHURA Biosciences, Inc.股票,TuHURA Biosciences, Inc.股票老虎,TuHURA Biosciences, Inc.股票老虎国际,TuHURA Biosciences, Inc.行情,TuHURA Biosciences, Inc.股票行情,TuHURA Biosciences, Inc.股价,TuHURA Biosciences, Inc.股市,TuHURA Biosciences, Inc.股票价格,TuHURA Biosciences, Inc.股票交易,TuHURA Biosciences, Inc.股票购买,TuHURA Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TuHURA Biosciences, Inc.(HURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供TuHURA Biosciences, Inc.(HURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}